ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2021, Vol. 13 ›› Issue (4): 325-.

• 临床研究 • 上一篇    下一篇

粉尘螨滴剂联合特布他林、孟鲁司特治疗小儿过敏性哮喘的疗效观察

目的:探究粉尘螨滴剂联合特布他林、孟鲁司特治疗小儿过敏性哮喘的疗效分析。
方法:选取2018年1月至2020年1月我院收治过敏性哮喘患儿80例为研究对象，随机分为观察组及对照组各40例。对照组给予特布他林联合孟鲁司特治疗，观察组给予粉尘螨滴剂联合特布他林、孟鲁司特治疗。比较两组患儿治疗效果；比较治疗前及治疗3个月后两组患儿炎症因子（白细胞介素-17、白细胞介素-10）、免疫情况（CD4+、CD8+）差异；比较治疗3个月内两组患儿不良反应发生率。
结果观察组治疗总有效率为95.0%（38/40），显著高于对照组80.0%（32/40），差异有统计学意义（P<0.05）。治疗3个月后，两组患儿白细胞介素-17、CD4+、CD8+指标水平较治疗前显著下降，且观察组低于对照组，差异有统计学意义（P<0.05）；白细胞介素10指标水平较治疗前显著上升，且观察组高于对照组，差异有统计学意义（P<0.05）。治疗3个月内，两组患儿不良反应发生率比较差异无统计学意义（P>0.05）。
结论:粉尘螨滴剂联合特布他林、孟鲁司特对小儿过敏性哮喘有较好治疗效果，可显著提升机体免疫功能，抑制炎症反应。   

  1. 450000 郑州，郑州大学附属儿童医院、河南省儿童医院、郑州儿童医院呼吸科变态反应室（李奕，沈照波）；200092 上海，上海交通大学附属新华医院呼吸科（华丽）
  • 出版日期:2021-08-25 发布日期:2021-12-10
  • 通讯作者: 沈照波，E-mail：shenzhaobo2006@126.com
  • 作者简介:李奕（1986-），女，医学硕士，主管药师。研究方向：儿科变态反应药理学
  • 基金资助:
    河南省医学科技攻关计划项目（LHGJ20190907）

Observation on the efficacy of dust mite drops combined with terbutaline and montelukast in the treatment of allergic asthma in children

Objective:To observe the efficacy of dust mite drops combined with terbutaline and montelukast in the treatment of allergic asthma in children.#br# Methods:A total of 80 children with allergic asthma admitted to our hospital from January2018 to January 2020 were selected as the study subjects. According to the random number table, they were divided into the experimental group and the control group with 40 cases each. The control group was treated with terbutaline combined with montelukast, while the experimental group was treated with dust mite dropscombined with terbutaline and montelukast. The therapeutic effect was compared between the two groups; the difference in inflammatory factors(IL-17,IL-10) and immune status(CD4+, CD8+) between the two groups before and 3 months aftertreatment were compared; the incidence of adverse reactions was compared between the two groups within 3months after treatment.#br# Results:The total effective rate of treatment in the experimental group(95.0%, 38/40) was significantly higher than that in the control group(80.0%, 32/40), with a statistically significant difference(P<0.05).After 3 months of treatment, the levels of IL-17, CD4+, and CD8+ in thetwo groups were significantly lower than those before treatment, and they werelower in experimental group than in control group(P<0.05);the level of IL-10 in the experimental group was significantly higher than that in the control group, and it was higher in experimental group than in control group(P<0.05). There was no significant difference in the incidence of adverse reactions during the 3-month treatment between the two groups(P>0.05).#br# Conclusion:Dust mite drops combined with terbutaline and montelukast are effective in the treatment of allergic asthma in children, which can significantly improve the immune function and inhibit the inflammatory response.   

  1. Children's Hospital Affiliated to Zhengzhou University，Zhengzhou 450000，China
  • Online:2021-08-25 Published:2021-12-10

PDF (PC)

5

摘要： 目的:探究粉尘螨滴剂联合特布他林、孟鲁司特治疗小儿过敏性哮喘的疗效分析。
方法:选取2018年1月至2020年1月我院收治过敏性哮喘患儿80例为研究对象，随机分为观察组及对照组各40例。对照组给予特布他林联合孟鲁司特治疗，观察组给予粉尘螨滴剂联合特布他林、孟鲁司特治疗。比较两组患儿治疗效果；比较治疗前及治疗3个月后两组患儿炎症因子（白细胞介素-17、白细胞介素-10）、免疫情况（CD4+、CD8+）差异；比较治疗3个月内两组患儿不良反应发生率。
结果观察组治疗总有效率为95.0%（38/40），显著高于对照组80.0%（32/40），差异有统计学意义（P<0.05）。治疗3个月后，两组患儿白细胞介素-17、CD4+、CD8+指标水平较治疗前显著下降，且观察组低于对照组，差异有统计学意义（P<0.05）；白细胞介素10指标水平较治疗前显著上升，且观察组高于对照组，差异有统计学意义（P<0.05）。治疗3个月内，两组患儿不良反应发生率比较差异无统计学意义（P>0.05）。
结论:粉尘螨滴剂联合特布他林、孟鲁司特对小儿过敏性哮喘有较好治疗效果，可显著提升机体免疫功能，抑制炎症反应。

关键词: 过敏性哮喘, 粉尘螨滴剂, 特布他林, 孟鲁司特, 儿童

Abstract: Objective:To observe the efficacy of dust mite drops combined with terbutaline and montelukast in the treatment of allergic asthma in children.
Methods:A total of 80 children with allergic asthma admitted to our hospital from January2018 to January 2020 were selected as the study subjects. According to the random number table, they were divided into the experimental group and the control group with 40 cases each. The control group was treated with terbutaline combined with montelukast, while the experimental group was treated with dust mite dropscombined with terbutaline and montelukast. The therapeutic effect was compared between the two groups; the difference in inflammatory factors(IL-17,IL-10) and immune status(CD4+, CD8+) between the two groups before and 3 months aftertreatment were compared; the incidence of adverse reactions was compared between the two groups within 3months after treatment.
Results:The total effective rate of treatment in the experimental group(95.0%, 38/40) was significantly higher than that in the control group(80.0%, 32/40), with a statistically significant difference(P<0.05).After 3 months of treatment, the levels of IL-17, CD4+, and CD8+ in thetwo groups were significantly lower than those before treatment, and they werelower in experimental group than in control group(P<0.05);the level of IL-10 in the experimental group was significantly higher than that in the control group, and it was higher in experimental group than in control group(P<0.05). There was no significant difference in the incidence of adverse reactions during the 3-month treatment between the two groups(P>0.05).
Conclusion:Dust mite drops combined with terbutaline and montelukast are effective in the treatment of allergic asthma in children, which can significantly improve the immune function and inhibit the inflammatory response.

Key words: Allergic asthma, Dust mite drops, Terbutaline, Montelukast, Children